There was no evidence for treatment-related normalization in SS-A, SS-B autoantibody titers, or β2-microglobulin, complement components 3 (C3) or C4, or hemolytic complement (CH50) levels (Supplemental Table 2). This evidence concerns the gene HLA-G and synovial sarcoma.